Rekvina Laboratories
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Rekvina Laboratories shifted its registered office within Vadodara to Laxmi Society, Old Padra Road, effective 23 September 2026. Its board on 23 September noted the resignation of managing director Amit Shah effective 11 September 2026 for personal reasons. The departure followed the resignation of company secretary Deepak Khandelwal effective 2 September. Amit Shah led the company alongside executive director and chief financial officer Surbhit Shah, with the listed entity reporting revenue of ₹1.27 crore from pharma goods trading in FY26 and a net loss of about ₹25.5 lakh. Trading in the shares resumed in January 2026 after a four-year suspension for listing-regulation non-compliance.
Powered by Tijori
Rekvina Laboratories shifted its registered office within Vadodara to Laxmi Society, Old Padra Road, effective 23 September 2026. Its board on 23 September noted the resignation of managing director Amit Shah effective 11 September 2026 for personal reasons. The departure followed the resignation of company secretary Deepak Khandelwal effective 2 September. Amit Shah led the company alongside executive director and chief financial officer Surbhit Shah, with the listed entity reporting revenue of ₹1.27 crore from pharma goods trading in FY26 and a net loss of about ₹25.5 lakh. Trading in the shares resumed in January 2026 after a four-year suspension for listing-regulation non-compliance.
Powered by Tijori
Rekvina Laboratories shifted its registered office within Vadodara to Laxmi Society on Old Padra Road with effect from 23 September 2026. Managing director Amit Shah resigned with effect from 11 September 2026, citing personal reasons. Deepak Khandelwal had resigned as company secretary effective 2 September 2026. Rekvina reported revenue of Rs.1.27 crore for the year to March 2026, entirely from trading of pharma goods, with a net loss of about Rs.25.5 lakh and negative net worth of Rs.1.23 crore. Trading in its shares had resumed in January 2026 after a suspension of nearly four years. An open offer that closed in July 2026 saw 14.4 lakh shares tendered at Rs.10 apiece, leaving the promoter group with about 64.3% and the public float at about 23%.
Powered by Tijori
Rekvina Laboratories shifted its registered office within Vadodara to Laxmi Society on Old Padra Road with effect from 23 September 2026. Managing director Amit Shah resigned with effect from 11 September 2026, citing personal reasons. Deepak Khandelwal had resigned as company secretary effective 2 September 2026. Rekvina reported revenue of Rs.1.27 crore for the year to March 2026, entirely from trading of pharma goods, with a net loss of about Rs.25.5 lakh and negative net worth of Rs.1.23 crore. Trading in its shares had resumed in January 2026 after a suspension of nearly four years. An open offer that closed in July 2026 saw 14.4 lakh shares tendered at Rs.10 apiece, leaving the promoter group with about 64.3% and the public float at about 23%.
Powered by Tijori
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Rekvina Laboratories do?
Rekvina Laboratories Ltd is committed to provide quality medication at affordable prices to the patients with a view to help bring down the healthcare costs.
Who are the competitors of Rekvina Laboratories?
Rekvina Laboratories major competitors are ANG Lifesciences, Shelter Pharma, Cian Healthcare, Shanmuga Hospital, Biofil Chem & Pharma, Phaarmasia, Vivimed Labs. Market Cap of Rekvina Laboratories is ₹55 Crs. While the median market cap of its peers are ₹61 Crs.
Is Rekvina Laboratories financially stable compared to its competitors?
Rekvina Laboratories seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Rekvina Laboratories pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Rekvina Laboratories latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Rekvina Laboratories allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Short Term Loans & Advances
How strong is Rekvina Laboratories balance sheet?
Balance sheet of Rekvina Laboratories is strong. But short term working capital might become an issue for this company.
Is the profitablity of Rekvina Laboratories improving?
No, profit is decreasing. The profit of Rekvina Laboratories is -₹0.14 Crs for Mar 2025, -₹0.02 Crs for Mar 2024 and ₹0 Crs for Mar 2023
Is the debt of Rekvina Laboratories increasing or decreasing?
Yes, The net debt of Rekvina Laboratories is increasing. Latest net debt of Rekvina Laboratories is ₹1.46 Crs as of Mar-26. This is greater than Mar-25 when it was ₹0.2 Crs.
Is Rekvina Laboratories stock expensive?
There is insufficient historical data to gauge this. Latest PE of Rekvina Laboratories is 0
Has the share price of Rekvina Laboratories grown faster than its competition?
Rekvina Laboratories has given better returns compared to its competitors. Rekvina Laboratories has grown at ~738.98% over the last 1yrs while peers have grown at a median rate of 4.72%
Is the promoter bullish about Rekvina Laboratories?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Rekvina Laboratories is 41.3% and last quarter promoter holding is 41.3%.
Are mutual funds buying/selling Rekvina Laboratories?
There is Insufficient data to gauge this.